-
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635
05 Sep 2025 18:00 GMT
… -Clinical Development at Aptevo Therapeutics (Nasdaq: APVO), during which she led … partnerships and out-licensing of assets, and helped position ZymoGenetics for … of Merck Research Laboratories and Amgen (Nasdaq: AMGN). BriaCell also announces that its …
-
Is Amgen Stock Underperforming the S&P 500?
02 Sep 2025 23:00 GMT
Headquartered in Thousand Oaks, California, Amgen Inc. (AMGN) discovers, develops, … to acquire promising pipeline assets that could drive long- … com On August 5, Amgen’s Q2 fiscal 2025 earnings … Market focus shifted to Amgen’s experimental weight-loss therapy …
-
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
25 Aug 2025 18:22 GMT
… worldwide sales, excluding China, of Amgen Inc.’s AMGN Imdelltra (tarlatamab … other assets under the terms of the existing collaboration with Amgen, including … ) broadened the approved use of Amgen’s Repatha (evolocumab) to include …
-
Weight-Loss Wasteland: 5 Obesity Assets That Failed
25 Aug 2025 04:32 GMT
… reason for this fanfare. Amgen itself has pushed MariTide hard … and a number of preclinical assets,” Bradner said. AMG 786, … investors had been expecting. Amgen crashed 11% in the aftermath … only partially rebounded.
Still, Amgen is moving forward with MariTide …
-
Amgen Stock Sinks As Market Eyes MariTide's Next Move
06 Aug 2025 18:37 GMT
… Sued By Eli Lilly, Amgen Over Drug Discount Program
Product … the strong quarterly performance, Amgen raised fiscal year 2025 … Amgen has had meaningful clinical and commercial success with assets … reiterate our Outperform rating.”
Amgen has some near-term …
-
Uncovering Potential: Amgen's Earnings Preview
04 Aug 2025 14:47 GMT
…
Unveiling the Story Behind Amgen
Amgen is a leader in … Otezla for inflammatory diseases. Amgen introduced its first cancer … portfolio.
Understanding the Numbers: Amgen's Finances
Market … equity capital.
Return on Assets (ROA): Amgen's financial …
-
Multispecific Antibodies Market Soars with Bispecific & Trispecific Therapeutics Assets in High Demand
25 Jul 2025 11:25 GMT
… Big Pharma Investment: Regeneron, Roche, Amgen, AstraZeneca, Innovent, Zymeworks, and … Landscape
Industry leaders include Roche, Amgen, Regeneron, Innovent, Zymeworks, Merus … filing patents and advancing multispecific assets through trial phases. Startups …
-
What Analysts Are Saying About Amgen Stock
21 Jul 2025 22:03 GMT
… how financial experts perceive Amgen. The following summary outlines … on Amgen analyst ratings.
Get to Know Amgen Better
Amgen is … Otezla for inflammatory diseases. Amgen introduced its first cancer … equity capital.
Return on Assets (ROA): Amgen's ROA …
-
Amgen Inc. (NASDAQ:AMGN) Q1 2025 Earnings Call Transcript
02 May 2025 13:09 GMT
… advance key late-stage pipeline assets, including MariTide and Olpasiran.
We … amp;A Session
Follow Amgen Inc (NASDAQ:AMGN) Follow Amgen Inc (NASDAQ:AMGN) We may use … 2025 Earnings Call.
Follow Amgen Inc (NASDAQ:AMGN) Follow Amgen Inc (NASDAQ:AMGN) We may use …
-
Where Amgen Stands With Analysts
24 Jun 2025 20:58 GMT
… on Amgen analyst ratings.
Get to Know Amgen Better
Amgen is … biosimilar portfolio.
Breaking Down Amgen's Financial Performance … capital.
Return on Assets (ROA): Amgen's ROA … demonstrates effective utilization of assets and strong financial performance. …